JSK Biomed's Mirajet Gains Global Investor Attention at Expand North Star

JSK Biomed, the company that developed the world's first needle-free laser injector, “Mirajet“ has attracted significant attention from global investors by participating in Dubai's “Expand North Star“ event. As the most prominent startup investment event globally, Expand North Star provides a platform for startups showcasing cutting-edge technology and innovative products. Companies worldwide aiming to expand into Middle Eastern and global markets are participating and gaining much attention for their innovations.

With support from the Seoul Economic Promotion Agency, the AGCC Accelerator facilitated connections between startups and investors at the event. The AGCC is an accelerator supported by the Dubai Multi Commodities Centre(DMCC), and it serves as a bridge helping innovative companies around the world enter global markets. By providing networks and resources, particularly in the Middle East and Asia, the AGCC supports startups in successfully establishing themselves in international markets.

During the exhibition and demo day, JSK Biomed showcased its flagship product, Mirajet. Mirajet is the world's first needle-free laser injector that uses laser pulses to administer medication through the skin, significantly reducing the pain and fear commonly associated with traditional needles. The technology is highly regarded for its needle-free design, eliminating the risk of infection and offering precise drug delivery, which makes it highly anticipated in the cosmetic medical field.

At the event, JSK Biomed discussed collaboration opportunities with key Middle Eastern investors and received positive signals regarding its entry into the regional market. With the demand for medical technology in the Middle East growing rapidly, there is strong anticipation that JSK Biomed's innovative products, such as Mirajet, will make a significant impact in the local market.

A representative from JSK Biomed stated, “The results from Expand North Star are very encouraging. We plan to work closely with local partners to achieve success in the Middle Eastern market. Using this opportunity as a stepping stone, we aim to further strengthen Mirajet's global presence.“
With the support of AGCC and Dubai DMCC, JSK Biomed has fully prepared for its entry into the Middle Eastern market, signaling the company's readiness to expand its activities into various countries shortly. The collaboration strengthens its global presence and positions the company to leverage regional growth opportunities.